Your Body's Hidden Balancing System: The Endocannabinoid System (ECS) and CBD's Role

Almost every article you read about CBD mentions the "endocannabinoid system." It may sound complicated, but the basic idea is quite simple: our bodies make their own signaling molecules that resemble compounds in cannabis. In this article we explain in plain language how this system was discovered, how it works, how CBD interacts with it, and what this information does and does not mean for health. Short explanations of the terms are on our glossary page.

What is the endocannabinoid system?

The story began with THC. While searching for what THC, the compound behind marijuana's effects, binds to in the brain, researchers identified a receptor called CB1 in 1990 (Matsuda 1990). It then became clear that the body makes its own molecules that bind to this receptor: anandamide was found in 1992 (Devane 1992) and 2-AG in 1995 (Mechoulam 1995). In 1993, a second receptor, CB2, was identified, found not in the brain but in immune cells (Munro 1993). That is where the system's name comes from: "endo" means from within, that is, the body's own cannabinoids.

Today the ECS is described as a widespread regulatory network involved in brain development and in many cognitive and bodily processes (Lu and Mackie 2021).

Parts of the system

How does it work?

Nerve cells in the brain "talk" to each other with chemical messages: one cell sends the message, the other receives it. The interesting thing about the endocannabinoid system is that the receiving cell can, when needed, turn back and tell the sending cell to "slow down a bit." Stimulated nerve cells quickly release anandamide and 2-AG; these molecules travel backward, bind to CB1 receptors on the cell sending the message, and reduce the amount of messenger it releases for a while (Wilson and Nicoll 2001). This backward signaling is the main way the system regulates short- and long-term changes at synapses; in some cases it has been shown to signal in other ways too (Castillo 2012). That is why the ECS is often compared to the brain's "fine-tuning" or "brake" system.

You can also take a look at our article on cannabinoid signaling, where we explain how this signaling works in more detail.

The "endocannabinoid deficiency" idea

Some researchers suggest that this system does not work well enough in pain conditions whose causes are not fully understood, such as migraine, fibromyalgia and irritable bowel syndrome. A review advocating this idea, called "clinical endocannabinoid deficiency," reports that anandamide levels in spinal fluid were found to be different in people with migraine (Russo 2016). But this is a hypothesis; it does not show that CBD works in these diseases. Indeed, in a 24-week study of 200 patients with fibromyalgia, 50 mg of CBD a day reduced pain less than placebo (Rasmussen 2026).

How does CBD interact with this system?

CBD (cannabidiol) is also a cannabinoid found in cannabis, but it approaches this system very differently from THC:

• It does not directly activate CB1: THC binds to CB1 and activates it, which is why it causes a high. In lab cell studies, CBD instead bound to a different site on CB1 and acted like a "modulator" that reduces the receptor's response to THC and 2-AG (Laprairie 2015).
• It may slow the breakdown of anandamide: CBD moderately inhibits the enzyme that breaks down anandamide. In a study of patients with schizophrenia, blood anandamide levels rose in those taking CBD (Leweke 2012).
• It has other targets too: In animal studies, targets outside the ECS, such as serotonin receptors, also appear to contribute to CBD's effects (Jantsch 2026).

These effects seen in the lab do not always produce the expected result in humans. For example, marijuana containing both THC and CBD caused less anxiety than marijuana containing only THC; but in people with high anxiety at the start, CBD did not prevent the anxiety caused by THC (Hutten 2022). In another study, CBD given beforehand did not reduce THC's negative effect on attention and thinking speed (Woelfl 2020).

What does this information mean for health?

A substance interacting with this system does not, on its own, show that it works for a disease. Only controlled studies, in which patients are randomly assigned to groups taking CBD or an inactive drug (placebo), can show that. Roughly, today's picture looks like this:

The evidence for other topics is summarized one by one in the CBD Guide.

Possible side effects and drug interactions

• Liver: In a controlled study in healthy adults, liver enzymes rose to more than 3 times the normal level in 5.6% of those taking CBD for 28 days; this was not seen in the placebo group (Florian 2025).
• Drug interactions: CBD can slow how the body breaks down some medicines. In healthy adults, the total blood level of citalopram rose by 43% (Salcedo 2026); in children with epilepsy, clobazam and its byproduct rose markedly (Geffrey 2015).
• Common side effects: In epilepsy studies, the most commonly reported side effects were sleepiness, fatigue, diarrhea and vomiting (Devinsky 2017).

Details are on the drug interactions and safety pages.

How was it used in the studies?

The following are only doses used in research (study doses; not a personal recommendation). In the liver safety study, healthy adults took 5 mg of CBD per kilogram of body weight per day, split into two doses, for 28 days; the researchers say they chose this dose within the range taken by people who use over-the-counter products (Florian 2025). In the epilepsy studies, 10–20 mg of the approved CBD medicine per kilogram per day was used (Devinsky 2017).

If you are considering CBD

After learning about the ECS, it is understandable that you might consider trying CBD. You can talk about the following with your doctor or pharmacist:

• Which complaint you are considering CBD for, and where the evidence stands on it.
• The medicines you take and possible interactions.
• Liver disease, pregnancy or breastfeeding.
• How to read a product label (label reading guide).

In Turkey, cannabis-derived products, including CBD, can be sold only in pharmacies (Law No. 7557, regulation of January 31, 2026). Those classed as medicines or health products are dispensed on prescription; no prescription requirement is stated for supplement products with at most 0.3% THC. As of October 2026, there is no approved CBD medicine in Turkey. Details are on our regulations page.

Conclusion

The endocannabinoid system is an important regulatory network that works with the body's own cannabinoids and fine-tunes communication between nerve cells. CBD interacts with this system in ways that differ from THC; but this interaction does not mean CBD works for a disease. Today, the area where this has been strongly shown is drug-resistant epilepsy syndromes treated with the approved CBD medicine.

Frequently asked questions

References